MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




Bowel Disease Therapy Fails Phase II Study

Porcine whipworm eggs are no better than placebo (October 14)

Disappointing results have been reported from a phase II clinical trial evaluating TSO (Trichuris suis ova, Coronado Biosciences) in patients with moderate-to-severe Crohn’s disease (CD).

TSO, the microscopic eggs of the porcine whipworm, is an investigational, orally administered, natural immunomodulator that regulates T-cells and pro-inflammatory cytokines.

The phase II TRUST-I study did not meet its primary endpoint of improving response, defined as a 100-point decrease in the Crohn’s Disease Activity Index (CDAI), nor the key secondary endpoint of remission, defined as achieving a CDAI score of less than 150 points.

In the overall patient population, the response rate of patients treated with TSO was not different from that of patients given placebo. In a predefined subset analysis, TSO showed a non-significant improved response in patients with CDAI scores greater than 290.

TRUST-I was a randomized, double-blind, placebo-controlled, U.S. study designed to evaluate the safety and efficacy of TSO in patients with CD. A total of 250 patients with moderate-to-severe CD were randomly assigned to receive either 7,500 ova (n = 125) or placebo (n = 125) once every 2 weeks for 12 weeks. The study’s primary endpoint was the induction of a response at 12 weeks, and the induction of remission was a key secondary endpoint.

Patients who completed the study had the option of enrolling in a 12-week open-label extension trial. All patients in the extension trial receive 7,500 ova once every 2 weeks.

Source: Coronado Biosciences; October 14, 2013.

More stories